Harvard Apparatus Regenerative Technology, Inc. (HRGN) stock

HRGNOTCSurgical & Medical Instruments & ApparatusFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 13, 2026Score 1/30

$2.21−0.02 (-0.72%)

Close on Oct 19, 2026Market cap $40.13MP/E –Yield –

Harvard Apparatus Regenerative Technology ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

No ebitda figures for Harvard Apparatus Regenerative Technology

Harvard Apparatus Regenerative Technology has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

More Harvard Apparatus Regenerative Technology figures

Where these numbers come from

Parsed from the XBRL in Harvard Apparatus Regenerative Technology's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-20 reverse split on Dec 22, 2017
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is HRGN.

Compare: HRGN vs PETV · HRGN vs OSRH · HRGN vs ICU · HRGN vs PLSE · HRGN vs VYCO

Revenue growth35.1% · median -9.5%

Gross margin7.5% · median 67.0%

Operating margin-643.0% · median -747.0%

Net margin-642.0% · median -752.8%

Company	Revenue	Growth
ICU	$2.17M	+145.7%
VYCO	$1.71M	-10.2%
OSRH	$1.71M	-50.4%
PLSE	$1.49M	+1637.2%
PETV	$1.18M	-9.5%
HRGN	$1.00M	+35.1%

Company

Exchange: OTC
Industry: Surgical & Medical Instruments & Apparatus
Fiscal year ends: December 31
Employees: 8
Auditor: CBIZ CPAs P.C.
SEC CIK: 1563665

Advertisement
300 × 250

See a number that looks wrong?